biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
23:33 Surgeons place a wireless brain implant for sight in a third blind person✦22:19 Close-together pregnancies may stack up on aging tests, review argues✦22:13 One immune-cell infusion held myeloma at bay 5 years in half of 20 patients✦22:10 High-dose omega-3 pills did not protect memory in a 2-year trial✦22:10 Daily aspirin did not slow aging-related decline; women slipped slightly✦16:38 Statin users had about double the dementia risk in two big health studies✦16:35 Anthropic lays out plans for its Claude AI to help invent new drugs✦16:31 FDA clears a test of a brain-fluid drain in early Alzheimer's, maker says✦23:33 Surgeons place a wireless brain implant for sight in a third blind person✦22:19 Close-together pregnancies may stack up on aging tests, review argues✦22:13 One immune-cell infusion held myeloma at bay 5 years in half of 20 patients✦22:10 High-dose omega-3 pills did not protect memory in a 2-year trial✦22:10 Daily aspirin did not slow aging-related decline; women slipped slightly✦16:38 Statin users had about double the dementia risk in two big health studies✦16:35 Anthropic lays out plans for its Claude AI to help invent new drugs✦16:31 FDA clears a test of a brain-fluid drain in early Alzheimer's, maker says
← All story threadsSTORY THREAD

Carvykti cell therapy given earlier in myeloma.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 29, 2026
    HALF FREE OF CANCER GROWTH 5 YEARS AFTER ONE DOSESmall trial · 20 patients

    One immune-cell infusion held myeloma at bay 5 years in half of 20 patients

    Five years after a single dose of the CAR-T therapy Carvykti, 10 of 20 people with returning myeloma were alive with no sign of the cancer growing and no further treatment.